Abstract: The present disclosure provides recombinant AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the recombinant AAV capsid proteins. The disclosure also provides methods of administering the virus vectors and vims capsids of the disclosure to a cell or to a subject in vivo.

Abstract: Healthy functional platelets are mass produced. A method for producing platelets, comprising: (1) a culture step of culturing megakaryocytes in a platelet producing medium in the presence of mechanical stress and platelet production promoting factors including MIF, NRDc, IGFBP2, TSP-1, PAI-1, and CCL5, and (2) a harvest step of harvesting the platelets obtained by the culture step; wherein the culture step comprises: (a) a step of promoting a release of the platelet production promoting factors from megakaryocytes by mechanical stress; and/or (b) a step of externally adding platelet production promoting factors including MIF, NRDc, and IGFBP2.

Abstract: A non-human papilloma pseudovirus or virus like particle has at least one papilloma capsid protein codon-optimized for expression in eukaryotic cells or cell lines. A pharmaceutical composition includes the non-human papilloma pseudovirus or virus like particle, and a diagnostic agent, an imaging agent, and a therapeutic agent. A non-human papilloma pseudovirus or virus like particle can be used as a medicament. A method for producing a non-human papilloma pseudovirus or virus like particle involves codon-optimizing of capsid proteins of non-human papillomaviruses for expression in eukaryotic cells, synthesizing of the sequences and cloning of the synthesized sequences into expression vectors, and producing non-human papilloma pseudovirus or virus like particles. ?-carrageenan can be used as transduction enhancer for non-human papilloma pseudovirus or virus like particles in vitro.

Abstract: A novel cell culture method for inducing differentiation of a pluripotent stem cell into trophoblast and an automatic culture apparatus therefor includes: a first step of culturing the pluripotent stem cell in a presence of a ROCK inhibitor during a first time period; a second step of culturing the pluripotent stem cell, which has been subjected to the first step, without the ROCK inhibitor during a second time period following the first time period; and a step of culturing the pluripotent stem cell, which has been subjected to the second step, in the presence of the ROCK inhibitor during a third time period following the second time period, in which the pluripotent stem cell is cultured in a state of being adhered to a cell culture substrate including a planar mesh through the first to third time periods.

Abstract: A method of measuring immunocompetence is described. This method provides a means for assessing the effects of diseases or conditions that compromise the immune system and of therapies aimed to reconstitute it. This method is based on quantifying T-cell diversity by calculating the number of diverse T-cell receptor (TCR) beta chain variable regions from blood cells.

Abstract: The present application relates to compositions comprising and methods of using a liposome comprising a pHLIP polypeptide, wherein a lipid bilayer of the liposome is substantially free of the pHLIP polypeptide.

Abstract: Embodiments relate to a modified cell engineered to comprise a modified TCR-CD3 complex, wherein the CD3?, ?-chain, CD3?, and/or CD3? chains of the modified TCR-CD3 complex are linked to one or more co-stimulatory signaling domains.

Abstract: The present invention relates to: recombinant adenoviruses, which have an excellent ability to be introduced into stem cells and can be easily introduced into stem cells even at a low concentration; stem cells comprising the same; a gene delivery composition; and a pharmaceutical composition. Stem cells into which adenoviruses are introduced, of the present invention, have excellent in vivo survivability and a treatment effect on tumor cells, and, when used as an anticancer drug, do not cause problems with respect to in vivo survival, hepatotoxicity and the like of stem cells so as to be particularly usable for systemic administration, and have an excellent anticancer effect even in small doses, thereby being widely usable as an anticancer drug using adenoviruses.

Abstract: Use of Cistanche deserticola polysaccharide (CDP) in promoting the proliferation and differentiation of female germline stem cells (FGSCs) is provided. Specifically, the addition of CDP in an in vitro cultivation system can promote the proliferation and differentiation of FGSCs, and especially can enhance the in vitro directed differentiation of FGSCs into oocytes, which provides a new research reference for studying the generation of oocytes in vivo and in vitro and also brings a new hope for research on physiological infertility.

Abstract: The present invention relates to an AAV vector carrying a predetermined hybrid HGF gene sequence. Use of the AAV vector of the present invention allows a hybrid HGF gene to be delivered to a subject at a high delivery yield.